ethyl 2-oxo-2-[2-(trifluoromethoxy)phenyl]acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 2-oxo-2-[2-(trifluoromethoxy)phenyl]acetate
• 英文别名: ethyl oxo[2-(trifluoromethoxy)phenyl]acetate；Ethyl 2-(trifluoromethoxy)benzoylformate
• 化学式: C₁₁H₉F₃O₄
• 分子量: 262.185
• InChiKey: AQQNQHIWZWZZIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 2-oxo-2-[2-(trifluoromethoxy)phenyl]acetate 在 叔丁基锂 、 水 、 氯化铵 作用下， 以 乙醚 、 正庚烷 、 四氢呋喃 为溶剂， 反应 20.5h， 生成 5-chloro-3-hydroxy-3-[2-(trifluoromethoxy)phenyl]-6-(trifluoromethyl)-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  EP1659121

  摘要：

  公开号：
• 作为产物：
  描述：

  三氟甲氧基苯 、 草酰氯单乙酯 在 四甲基乙二胺 、 仲丁基锂 作用下， 以 四氢呋喃 、 环己烷 为溶剂， 反应 2.0h， 以87%的产率得到ethyl 2-oxo-2-[2-(trifluoromethoxy)phenyl]acetate
  参考文献：
  名称：

  2-、3- 和 4-（三氟甲氧基）苯基锂：多功能中间体，可提供各种新型有机氟化合物

  摘要：

  用仲丁基锂和亲电试剂连续处理（三氟甲氧基）苯，可得到以前无法获得的邻位取代衍生物。在一般优良的产量。2-(三氟甲氧基)苯基锂是关键中间体。通过卤素-金属与丁基锂或叔丁基锂的相互转化，可以很容易地从相应的 3- 和 4- 溴前体生成 3- 和 4- 异构体。用 11 种不同的亲电子试剂（B(OH)2、OH、Br、I、CH3、EtOH、CHO、COCOOEt、COCH2COOEt、COOH、CN）捕获 2-、3- 和 4-（三氟甲氧基）苯基锂后，得到预期产物通常以高产率（高达 95%）形成。只有尝试亲核添加。2-(三氟甲氧基)苯基锂转化为环氧乙烷未成功。这种失败暂时归因于氟-锂相互作用导致的亲核性降低。构象受限的类似物 - 即 2,2-difluoro-1,3-benzodioxol-4-phenyllithium 及其 5-fluoro- 和 5-bromo-取代的同类物 - 确实与环氧乙烷顺利反应，以普通产率提供加合物。[在

  DOI：

  10.1002/1099-0690(200102)2001:4<691::aid-ejoc691>3.0.co;2-a

文献信息

• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• 1,3-Dihydro-2h-indol-2-one derivative
  申请人：Kumagai Toshihito

  公开号：US20060276449A1

  公开（公告）日：2006-12-07

  A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R 1 is a halogen atom, a C 1 to C 4 alkyl group, etc., and R 2 is a hydrogen atom, a halogen atom, etc., or R 2 is in the 6-position of the indol-2-one and R 1 and R 2 join together to form a C 3 to C 6 alkylene group, R 3 is a halogen atom, a hydroxyl group, etc., and R 4 is a hydrogen atom, a halogen atom, a C 1 to C 4 alkyl group, etc., or R 4 is in the 3-position of the phenyl and R 3 and R 4 join together to form a methylenedioxy group, R 5 is a hydrogen atom or a fluorine atom, R 6 is an ethylamino group, a dimethylamino group, etc., R 7 is a C 1 to C 4 alkoxy group, and R 8 is a C 1 to C 4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

  公式1所表示的1,3-二氢吲哚-2-酮衍生物（其中R1是卤素原子、C1到C4烷基等，R2是氢原子、卤素原子等，或R2位于吲哚-2-酮的6位，且R1和R2结合形成C3到C6烷基，R3是卤素原子、羟基等，R4是氢原子、卤素原子、C1到C4烷基等，或R4位于苯环的3位，且R3和R4结合形成亚甲二氧基基团，R5是氢原子或氟原子，R6是乙基氨基基团、二甲基氨基基团等，R7是C1到C4烷氧基基团，R8是C1到C4烷氧基基团），或该衍生物的药学上可接受的盐。这是一种新型化合物，具有对抗arginine-vasopressin V1b受体的拮抗活性。
• 1,3-dihydro-2H-indol-2-one derivative
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US07528124B2

  公开（公告）日：2009-05-05

  A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

  公式1表示的是1,3-二氢吲哚-2-酮衍生物（其中R1是卤素原子、C1至C4烷基等，R2是氢原子、卤素原子等，或者R2位于吲哚-2-酮的6位，R1和R2结合形成C3至C6烷基，R3是卤素原子、羟基等，R4是氢原子、卤素原子、C1至C4烷基等，或者R4位于苯环的3位，R3和R4结合形成甲氧基二氧杂环丙基，R5是氢原子或氟原子，R6是乙基氨基基、二甲基氨基基等，R7是C1至C4烷氧基，R8是C1至C4烷氧基），或该衍生物的药学上可接受的盐。这是一种新型化合物，具有对抗arginine-vasopressin V1b受体的拮抗活性。
• 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US08030499B2

  公开（公告）日：2011-10-04

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  本发明旨在提供一种对精氨酸加压素V1b受体相关的病理状况有效的药物。更具体地说，本发明旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、饮食失调、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫性疾病、脱发等具有治疗或预防作用的药物。经过密集研究，发现了一种新型的1,3-二氢吲哚-2-酮化合物和一种与杂环芳香环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性、良好的脑穿透性和高血浆浓度，从而实现了上述目标。
• 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1659121A1

  公开（公告）日：2006-05-24

  A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

  一种由式 1 表示的 1,3-二氢-2H-吲哚-2-酮衍生物（其中 R1 是卤素原子、C1 至 C4 烷基等，R2 是氢原子、卤素原子等，或 R2 位于吲哚-2-酮的 6 位，R1 和 R2 连接形成 C3 至 C6 亚烷基，R3 是卤素原子、羟基等、和 R4 是氢原子、卤素原子、C1 至 C4 烷基等，或 R4 位于苯基的 3 位，R3 和 R4 连接在一起形成亚甲基二氧基，R5 是氢原子或氟原子，R6 是乙氨基、二甲基氨基等，R7 是 C1 至 C4 烷氧基，R8 是 C1 至 C4 烷氧基），或该衍生物的药学上可接受的盐。这是一种新型化合物，具有拮抗芦丁-血管加压素 V1b 受体的活性。